Skip to main content

Table 3 Comparison of general information between two groups

From: Discovery and validation of PZP as a novel serum biomarker for screening lung adenocarcinoma in type 2 diabetes mellitus patients

General information T2DM T2DM + LAC P value
Gender (male/female) 23/17 19/21 0.371
Hypoglycemic therapy (A/B)a 27/13 26/14 0.813
Age (years) 61.05 ± 9.78 64.68 ± 7.10 0.137
AFP (ng/ml) 2.70 ± 1.17 3.21 ± 1.57 0.101
CEA (ng/ml) 2.11 ± 1.09 3.27 ± 3.72 0.304
CA125 (U/ml) 9.50 ± 4.86 12.34 ± 15.66 0.693
CA199 (U/ml) 14.41 ± 10.44 27.51 ± 68.25 0.994
FPG (mmol/L) 7.95 ± 1.91 7.41 ± 2.55 0.287
  1. aA, insulin or insulin-dependent therapies; B, insulin-independent therapies or no treatment
\